

Table of Contents:

Adverse Event Reporting SOPs for Drugs & Biologics

Two Previous Teleconferences About SOPs	4
Dr. Sharlin's Credentials	5
Outline Of This Presentation	6
Three Common Compliance Problems with SOPs	7
Purpose and Benefits of SOPs	8
Summary of SOP Development, Diagram	9
Summary of SOP Development, Diagram (2)	10
Summary of SOP Development, Diagram (3)	11
How Reviewers Examine Safety Data	12
How Reviewers Examine Safety Data (2)	13
A Reviewer's Sources of Information for a Safety Review	14
How To Improve A Submission Using Information From the Reviewer Guidance on Evaluating Safety Data	15
How To Improve A Submission Using Information From the Reviewer Guidance on Evaluating Safety Data (2)	16
April 2007 Guidance for Clinical Investigators, Sponsors and IRBs; AE Reporting – Improving Human Subject Protection (problem statement and participants)	17
Flowchart of Current AE Reporting Relationships (summary of April 2007 AE guidance)	18
Flowchart of FDA Recommended AE Reporting Relationships (summary of April 2007 AE guidance)	19
April 2007 Guidance for Clinical Investigators, Sponsors and IRBs; AE Reporting – Improving Human Subject Protection (Conclusions)	20
In August 2010 Electronic Safety Reporting Becomes Mandatory	21
SOP Format: Section Headings	22
SOP Format: Details	23
How to Change Model SOPs	24

Required Activities For Each New SOP.....	25
Factors That Affect Modification of Model SOPs.....	26
Features of the Model SOPs	27
How To Use SOP Deliverables.....	28
Model SOP #1, IND Safety Reporting.....	29
Model SOP #2, IND Annual Reports.....	30
Model SOP #3, Postmarketing Safety Reporting for Drugs and Biologics: Responsibilities.....	31
Model SOP #4, Postmarketing Safety Reporting for Drugs and Biologics: Content.....	32
Model SOP #5, Validation of AE Data Capture Systems	33
Model SOP #6, Data Monitoring Committee	34
Model SOP #7, Statistical Analysis of AE Data.....	35
Model SOP #8, MedDRA Coding of AE Data	36
Six Useful AE-Related Docs to Download From www.SpeedUpFDA.com.....	37
Summary of Teleconference; Adverse Event Reporting SOPs for Drugs and Biologics	38
Next steps	39
Joshua Sharlin, Ph.D., Resume	40